Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Columbus, Ohio 43210


Purpose:

To determine the safety and efficacy of the combination of Etanercept and Docetaxel in patients with advanced solid tumors for which there is no standard treatment.


Criteria:

Inclusion Criteria: - Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists. - Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option: - Non-Small Cell Lung - Breast - Head and Neck - Esophageal - Stomach - Ovarian carcinomas - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 - Life expectancy of at least 12 weeks. - Must have adequate organ function - Peripheral Neuropathy must be less than Grade 2


NCT ID:

NCT00201812


Primary Contact:

Principal Investigator
Miguel Villalona
Ohio State University


Backup Contact:

N/A


Location Contact:

Columbus, Ohio 43210
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.